Synaptogenix, Inc. - SNPX STOCK NEWS

Synaptogenix, Inc (Nasdaq: SNPX), focused on regenerative therapeutics for neurodegenerative disorders, will participate at the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. Dr. Daniel L. Alkon, President and Chief Scientific Officer, is scheduled to present on September 29 at 2:40 p.m. ET. The company is advancing its candidate, Bryostatin-1, which has shown promise in Alzheimer's and Fragile X syndrome. It holds Orphan Drug Designation for Bryostatin-1 for Fragile X. The FDA-approved candidate has been tested in over 1,500 participants, providing a substantial safety data base for future trials.

Synaptogenix, Inc. (Nasdaq: SNPX) will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference from September 13-15, 2021. Dr. Daniel Alkon, President and Chief Scientific Officer, will outline the company’s advancements in developing regenerative therapeutics for neurodegenerative disorders. Synaptogenix focuses on Bryostatin-1, which has shown potential in treating Alzheimer's disease and Fragile X syndrome and has a robust safety data background from over 1,500 participants in prior studies.

Synaptogenix, Inc. (Nasdaq: SNPX) announced a memorandum of understanding with Nemours A.I. DuPont Hospital for Children to initiate a clinical trial using Bryostatin to treat Fragile X syndrome. This partnership aims to explore Bryostatin's effects on children and young adults, building on positive preclinical studies that suggest its potential in addressing both intellectual disabilities and behavioral issues associated with Autism Spectrum Disorder. The FDA has previously granted Orphan Drug Status to Bryostatin for its treatment of Fragile X, backing its regenerative properties in neurodegeneration.

Synaptogenix, Inc. (SNPX) announced that its abstract titled "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease Patients" is now available for presentation at the Alzheimer's Association International Conference. The analysis indicates significant therapeutic efficacy of Bryostatin in advanced Alzheimer's patients, with a p-value of P<.001, showcasing an improvement of over +4.0 in Severe Impairment Battery scores. The company is also conducting a NIH-sponsored six-month clinical trial to further assess Bryostatin's effects.

Synaptogenix, Inc. (Nasdaq: SNPX) announced a conference call on July 26, 2021, to discuss findings from its abstract presented at the Alzheimer's Association International Conference. The call will feature CEO Dr. Alan Tuchman and President Dr. Daniel Alkon, who will address live Q&A. Synaptogenix is focused on therapies for neurodegenerative diseases, primarily through its lead candidate, Bryostatin-1, which has shown promise in Alzheimer's and Fragile X syndrome. The FDA has granted Orphan Drug Designation for Bryostatin-1 in treating Fragile X syndrome.

Synaptogenix, Inc. (Nasdaq: SNPX) announced that their abstract for Bryostatin-1, a leading candidate for treating Alzheimer's disease, has been accepted at the Alzheimer's Association International Conference from July 26-30, 2021. The poster presentation will discuss how Bryostatin significantly improved cognitive functions in advanced AD patients above their baseline levels. Dr. Daniel Alkon highlighted the promising data from Phase 2 trials, suggesting notable cognitive enhancements compared to placebo controls. Synaptogenix has also explored Bryostatin's efficacy in other neurodegenerative disorders.

Synaptogenix (Nasdaq: SNPX), a biopharmaceutical company focused on neurodegenerative diseases, announced a new patent awarded by the U.S. Patent Office for methods to induce synaptogenesis using growth factor activating compounds. This patent is particularly relevant for the lead drug, Bryostatin-1, which targets synaptic growth factors and aims to prevent neuronal death. Bryostatin has shown potential in treating Alzheimer's, Parkinson's, multiple sclerosis, and Fragile X syndrome. The company has a significant safety database from prior cancer studies involving over 1,500 participants.

Synaptogenix, Inc. (SNPX) announced that Dr. Daniel Alkon, President and CSO, will appear on TD Ameritrade Network's "The Watch List" on June 25, 2021, at 1:20 PM ET. He will discuss Synaptogenix's lead drug Bryostatin-1, focusing on its regenerative mechanism for treating Alzheimer's disease and its implications for future therapies following Biogen's recent drug approval. Synaptogenix is developing therapies for neurodegenerative diseases and has received Orphan Drug Designation for Bryostatin-1 aimed at Fragile X syndrome, highlighting the drug's clinical significance.

On June 14, 2021, Synaptogenix (Nasdaq: SNPX) announced a private placement financing to raise approximately $12.5 million. This funding will primarily support the ongoing Phase 2b trial of Bryostatin-1 for Alzheimer's disease, sponsored by the NIH, and further R&D for new indications. Each Unit consists of one share of common stock and one warrant priced at $7.547. The transaction, set to close on June 16, 2021, subject to customary conditions, reflects strong support from existing institutional shareholders.